Numerous studies in animal models and cell lines have reported the involvement of EPHX2 in a variety of metabolic diseases, including cardiovascular diseases (CVD), hypertension, Non-alcoholic fatty liver disease (NAFLD), and diabetes, highlighting the potential benefits of its inhibition [1,21]. Here, EPHX2 is linked to metabolic dysfunction-associated steatotic liver disease.